Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05867589
Other study ID # KY20230428-02
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2023
Est. completion date December 31, 2025

Study information

Verified date May 2023
Source Nanjing First Hospital, Nanjing Medical University
Contact Feng Wang
Phone 02552271491
Email fengwangcn@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of fibroblast activating protein receptor imaging agent [68Ga]/ Fluorine [18F] -fibroblast activating protein inhibitor (68Ga/18F-FAPI-04) in clinical application and to verify its effectiveness in the diagnosis of cardiovascular diseases.


Description:

The implementation of this project will promote the research of PET-MRI molecular imaging using the new nuclide imaging with the target of FAP combined with the MRI T1 mapping and ECV measurement technology, realize the fusion of nuclear medicine and magnetic resonance technology in a real sense, dynamically monitor the occurrence and development of myocardial fibrosis in heart failure at an early stage, and establish a complete set of myocardial fibrosis imaging programs. To provide an important basis for the exploration of anti-fibrosis therapy in heart failure and accelerate the pace of clinical transformation of this protocol.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Voluntary subjects, patients or their legal representatives to sign informed consent; 2. There was no limitation on the gender of the volunteers, whose age ranged from 18 to 85 years old, including the cut-off value; 3. Myocardial injury caused by various causes was found by other imaging methods (cardiac ultrasound, coronary angiography, coronary CT, cardiac MRI, etc.); 4. Kidney GFR > 50 ml/min, ERPF > 280 ml/min, platelet count (PLT) > 75 000/µL, leukocyte (WBC) > 3000/µL, alanine aminotransferase ALT, aspartate aminotransferase AST < 3 times the normal value. Exclusion Criteria: 1. Allergic to the same drugs (drugs with similar chemical or biological components to fibroblast activating protein inhibitors), allergic constitution or currently suffering from allergic diseases; 2. Clinical investigators who are currently conducting clinical studies on other drugs, or who have participated in any drug (excluding vitamins and minerals); 3. Have other clinical problems that are difficult to control (such as HIV, hepatitis C virus infection or active hepatitis B, or other severe chronic infections and serious mental, neurological, respiratory and other diseases); 4. Red blood cell RBC is less than 4×1012, white blood cell WBC is less than 3×109, hemoglobin is less than 80g/L, PLT is less than 75,000 ×109; 5. Significantly abnormal liver and kidney function, GFR less than 20 ml/min; 6. Cardiac ejection fraction (EF) was assessed to be less than 10%; 7. The expected survival time is less than half a year; Coronary stent implantation within 2 weeks or coronary artery bypass graft within 6 months; 8. Severe acute concomitant disease or severe refractory mental disorder; 9. Pregnant and lactating women (pregnancy is defined as positive in blood pregnancy studies); 10. Patients whose physical conditions are not suitable for radioactive examination; 11. Patients with metal implants (pacemakers, etc.) or spatial claustrophobia or other MRI related contraindications; 12. Any situation that the presiding officer of this study believes may cause harm or potential harm to any link related to this test.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
68Ga/18F-FAPI-04
Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.

Locations

Country Name City State
China Nanjing First Hospital Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Nanjing First Hospital, Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of 68Ga/18F-FAPI-04 Uptake Patterns by Regional SUV Values 68Ga/18F-FAPI-04 uptake patterns will be assessed in regions of interest (ROIs) which relevant to myocardial fibrosis pathology. Standard uptake value (SUV) will be calculated for each ROI, and standardized uptake value ratios (SUVRs) will be calculated by normalizing SUV of ROIs to the SUV of relevant reference region. 31 months
Primary Safety and Tolerability Profile Measured by Adverse Events (AEs) Safety and tolerability profile for the administration of 68Ga/18F-FAPI-04 and positron emission tomography (PET) scanning are measured by number of participants with adverse events (AEs). 31 months
See also
  Status Clinical Trial Phase
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Not yet recruiting NCT05954559 - High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment Phase 4
Recruiting NCT03176862 - Left Ventricular Fibrosis in Chronic Kidney Disease N/A
Recruiting NCT06039969 - Evaluate Aerobic Exercise on Myocardial Fibrosis and Intestinal Flora in Dilated Cardiomyopathy Diagnosed First Time.
Not yet recruiting NCT06059287 - The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics N/A
Completed NCT00879060 - Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy Phase 4
Completed NCT02834104 - Validation of Fibrosis Quantification Using T1 Mapping Against Histology as Reference and Comparison With Fibrosis Biomarkers N/A
Active, not recruiting NCT04444128 - IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
Recruiting NCT03191461 - Myocardial Perfusion and Fibrosis in Cancer Survivors
Recruiting NCT02428374 - Role of Immune Responses After Acute Myocardial Infarction Phase 4
Not yet recruiting NCT06326970 - SPECT Fibroblast Activation Protein Imaging in Patients With Cardiac Disease
Completed NCT02432885 - Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial Phase 3
Completed NCT04397198 - The Assessment Of Myocardial Viability Based On CTA/MRI Hybrid Models
Recruiting NCT03405987 - Association of T1-mapping and LV Strain Analysis by CMR
Completed NCT01160471 - Noninvasive Imaging of Heart Failure: A Pilot Study
Completed NCT03422770 - Ultrasonic Markers for Myocardial Fibrosis and Prognosis in Aortic Stenosis N/A
Not yet recruiting NCT03515291 - A Trial of Cardiac Injections of iMP Cells During CABG Surgery Phase 2
Recruiting NCT02670031 - Response of the Myocardium to Hypertrophic Conditions in the Adult Population
Terminated NCT02012725 - Molecular MRI of the Fibrotic Heart N/A
Completed NCT02727725 - An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images N/A